BioMarin Pharmaceutical Management
Management criteria checks 1/4
BioMarin Pharmaceutical's CEO is Alexander Hardy, appointed in Dec 2023, has a tenure of 2.58 years. total yearly compensation is $21.93M, comprised of 5.2% salary and 94.8% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €11.36M. The average tenure of the management team and the board of directors is 2.5 years and 2.6 years respectively.
Key information
Alexander Hardy
Chief executive officer
US$21.9m
Total compensation
| CEO salary percentage | 5.16% |
| CEO tenure | 2.6yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.5yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$269m |
| Dec 31 2025 | US$22m | US$1m | US$349m |
| Sep 30 2025 | n/a | n/a | US$520m |
| Jun 30 2025 | n/a | n/a | US$657m |
| Mar 31 2025 | n/a | n/a | US$524m |
| Dec 31 2024 | US$15m | US$1m | US$427m |
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$257m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Compensation vs Market: Alexander's total compensation ($USD21.93M) is above average for companies of similar size in the Italian market ($USD6.17M).
Compensation vs Earnings: Alexander's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Alexander Hardy (57 yo)
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023 having joined in December 2023. He had been Chief Executive Officer at Ge...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$21.93m | 0.11% € 11.4m | |
| CFO & Executive VP of Finance | 6.5yrs | US$6.83m | 0.064% € 6.5m | |
| Executive VP & CTO | no data | US$5.69m | 0.038% € 3.9m | |
| Executive VP & Chief Commercial Officer | 2.2yrs | US$5.71m | 0.0038% € 390.7k | |
| Executive VP and Chief Research & Development Officer | 1.8yrs | US$7.17m | 0.027% € 2.7m | |
| VP, Chief Accounting Officer & Principal Accounting Officer | less than a year | no data | no data | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | no data | no data | |
| Executive Vice President | less than a year | no data | no data | |
| Executive VP | 22.5yrs | US$5.06m | 0.041% € 4.2m | |
| Executive VP & Chief People Officer | 7.5yrs | no data | no data | |
| Senior Vice President of Technical Development | 4.8yrs | no data | no data | |
| Executive VP | 2.5yrs | no data | no data |
Experienced Management: 1BMRN's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$21.93m | 0.11% € 11.4m | |
| Independent Director | 2.6yrs | US$501.29k | 0.0070% € 716.9k | |
| Independent Chair of the Board | less than a year | US$451.23k | 0.0075% € 767.0k | |
| Independent Director | 10yrs | US$509.04k | 0.017% € 1.7m | |
| Independent Director | 1.4yrs | US$492.79k | 0.0053% € 540.0k | |
| Independent Director | 5.4yrs | US$502.79k | 0.014% € 1.5m | |
| Independent Director | 8.8yrs | US$509.54k | 0.018% € 1.9m | |
| Independent Director | 2.6yrs | US$493.66k | 0.0070% € 716.9k | |
| Independent Director | 7yrs | US$505.04k | 0.018% € 1.8m | |
| Independent Director | 2.6yrs | US$487.04k | 0.0070% € 716.9k |
Experienced Board: 1BMRN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/28 03:36 |
| End of Day Share Price | 2026/07/28 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 47 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ying Huang | Barclays |
| Eliana Merle | Barclays |